Office-based practice and opioid-use disorders. [N Engl J Med. 2003] - PubMed

loading

Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction. [Ann Intern Med. 2003]
Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
Resnick RB. Ann Intern Med. 2003 Feb 18; 138(4):360.
Buprenorphine: effective treatment of opioid addiction starts in the office. [Am Fam Physician. 2006]
Buprenorphine: effective treatment of opioid addiction starts in the office.
Fiellin DA. Am Fam Physician. 2006 May 1; 73(9):1513-4.
Review Narrative review: buprenorphine for opioid-dependent patients in office practice. [Ann Intern Med. 2008]
Review Narrative review: buprenorphine for opioid-dependent patients in office practice.
Sullivan LE, Fiellin DA. Ann Intern Med. 2008 May 6; 148(9):662-70.
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. [N Engl J Med. 2003]
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, et al. N Engl J Med. 2003 Sep 4; 349(10):949-58.
Review Recent advances in the treatment of opiate addiction. [Curr Psychiatry Rep. 2004]
Review Recent advances in the treatment of opiate addiction.
Fudala PJ, Woody GW. Curr Psychiatry Rep. 2004 Oct; 6(5):339-46.

Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. [Drug Alcohol Depend. 2009]
Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.
Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Drug Alcohol Depend. 2009 Jan 1; 99(1-3):132-40. Epub 2008 Sep 19.
Review Training physicians to treat substance use disorders. [Curr Psychiatry Rep. 2008]
Review Training physicians to treat substance use disorders.
Polydorou S, Gunderson EW, Levin FR. Curr Psychiatry Rep. 2008 Oct; 10(5):399-404.
Review Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. [Ann Intern Med. 2006]
Review Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.
Alford DP, Compton P, Samet JH. Ann Intern Med. 2006 Jan 17; 144(2):127-34.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Office-based practice and opioid-use disorders.
Office-based practice and opioid-use disorders.
N Engl J Med. 2003 Sep 4 ;349(10):928-30.

PubMed
Manipulation of stem cell proliferation and lineage commitment: visualisation of...
Manipulation of stem cell proliferation and lineage commitment: visualisation of label-retaining cells in wholemounts of mouse epidermis.
Development. 2003 Nov ;130(21):5241-55. Epub 2003 Sep 3 .

PubMed
Mature results of a randomized phase II multicenter study of exemestane versus t...
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Ann Oncol. 2003 Sep ;14(9):1391-8.

PubMed
Persistent central nervous system effects of an adverse early environment: clini...
Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies.
Physiol Behav. 2003 Aug ;79(3):471-8.

PubMed
The presence of the casein kinase II phosphorylation sites of Vpu enhances the C...
The presence of the casein kinase II phosphorylation sites of Vpu enhances the CD4(+) T cell loss caused by the simian-human immunodeficiency virus SHIV(KU-lbMC33) in pig-tailed macaques.
Virology. 2003 Sep 1 ;313(2):435-51.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed